Natera, Inc. logo

Natera, Inc. (NTRA) Q1 2026 Earnings

NTRA·Reported May 7, 2026·After market close

Natera, Inc. reported Q1 2026 revenue of $696.6M (+38.8% YoY), beat analyst consensus of $617.1M by $79.5M. Diluted EPS came in at $-0.56 (-12.0% YoY), missed the $-0.53 consensus by $0.03. Natera, Inc. reports across 4 business segments, led by Women’s Health, Oncology, and Organ Health.

Revenue
$696.6Mbeat by $79.5M
Consensus: $617.1M
Diluted EPS
$-0.56missed by $0.03
Consensus: $-0.53
SEC

SEC Filings

Earnings release8-K · 0001628280-26-032101
Quarterly report10-Q · 0001628280-26-032478

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Natera, Inc.'s Q1 2026 earnings report.

Natera, Inc. (NTRA) reported Q1 2026 earnings on May 7, 2026 after market close.

Natera, Inc. reported revenue of $696.6M and diluted EPS of $-0.56 for Q1 2026.

Revenue beat the consensus estimate of $617.1M by $79.5M. EPS missed the consensus estimate of $-0.53 by $0.03.

Compared to the same quarter a year prior, revenue grew 38.8% from $501.8M a year earlier and diluted EPS declined 12.0% from $-0.50.

You can read the 8-K earnings release (0001628280-26-032101) and the 10-Q periodic report (0001628280-26-032478) directly on SEC EDGAR. The filing index links above go to sec.gov.